Status:
COMPLETED
A Study to Test If Giving Remune (an HIV Vaccine) Can Improve the Immune Systems of HIV-Positive Patients Who Are Also Participating in ACTG 328
Lead Sponsor:
National Institute of Allergy and Infectious Diseases (NIAID)
Conditions:
HIV Infections
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
The purpose of this study is to determine the effects of an HIV vaccine (Remune) on the immune system. This study involves patients who have received at least 60 weeks of anti-HIV therapy, either alon...
Detailed Description
Proliferative responses to HIV antigens are either absent or of small magnitude in HIV-infected patients, even in the early stages of infection when vigorous proliferative responses to recall antigens...
Eligibility Criteria
Inclusion Criteria
Patients may be eligible for this study if they:
- Have completed at least 60 weeks of treatment on ACTG 328.
- Are willing to continue on their assigned ACTG 328 treatment until after they have completed 24 weeks on this substudy.
- Have a viral load less than or equal to 2,000 copies/ml.
Exclusion Criteria
Patients will not be eligible for this study if they:
- Have an active opportunistic (HIV-related) infection.
- Are pregnant or breast-feeding.
- Have taken or are taking certain medications that are prohibited.
Key Trial Info
Start Date :
Trial Type :
INTERVENTIONAL
End Date :
November 1 2005
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT00000943
End Date
November 1 2005
Last Update
October 29 2021
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Univ. of Iowa Healthcare, Div. of Infectious Diseases
Iowa City, Iowa, United States, 52242
2
NY Univ. HIV/AIDS CRS
New York, New York, United States